Why Tuberculocidal Claims No Longer Reflect Disinfectant Efficacy

Despite updated guidance and a growing range of innovative Environmental Protection Agency (EPA)-registered disinfectants, many healthcare facilities still question whether a tuberculocidal, or tuberculosis (TB), kill claim is necessary for healthcare surface disinfectants.

^{Source: https://www.cdc.gov/tb/causes/index.html}

The short answer: no current federal regulation identified in this review requires a TB claim for environmental surface disinfectants.

In plain language, a TB claim can demonstrate a disinfectant’s activity against Mycobacterium tuberculosis, but it should not be treated as a universal proxy for whether a product is appropriate for all healthcare surface disinfection needs.

Our June 2026 commentary in the American Journal of Infection Control (AJIC) examines the historical and regulatory context behind this longstanding misconception and makes the case for a modern, risk-based approach to disinfectant selection.

The origins of the TB claim benchmark

To understand why the TB claim became so entrenched in healthcare practice, it helps to trace its origins. In 1939, microbiologist Earle Spaulding introduced a risk-based framework for disinfection and sterilization that classified disinfectant levels as low, medium, and high (based on the intrinsic resistance of microorganisms). Within Spaulding’s framework, intermediate-level disinfection came to be associated with the ability to inactivate Mycobacterium tuberculosis, an organism recognized as relatively resistant to disinfectants. As a result, tuberculocidal activity was historically viewed as evidence of a higher level of disinfectant efficacy than low-level claims alone.

That classification made practical sense for its era. In the early 1990s, the Occupational Safety and Health Administration’s (OSHA) Bloodborne Pathogens Standard and related enforcement policy contributed to the use of tuberculocidal disinfectants or diluted bleach for decontaminating surfaces contaminated with blood or other potentially infectious materials. This likely helped establish the TB claim as a familiar benchmark in facility policies, even though it should not be interpreted as a universal requirement for healthcare-grade environmental surface disinfectants.

In 1997, OSHA revised its interpretation of an “appropriate” disinfectant under the Bloodborne Pathogens Standard to include EPA-registered disinfectants labeled effective against human immunodeficiency virus type 1 (HIV-1) and hepatitis B virus (HBV). This interpretation effectively eliminated the need to use a tuberculocidal disinfectant to comply with the standard for decontaminating surfaces contaminated with blood or other potentially infectious materials, provided the surfaces have not been contaminated with agents, volumes or concentrations for which higher-level disinfection is recommended. Yet the perception persisted, likely reinforced by internal facility policies that were not consistently revisited as guidance evolved.

What current federal requirements and guidance actually say

Today, federal requirements and guidance from the Centers for Disease Control and Prevention (CDC), OSHA, EPA and The Joint Commission (TJC) support a consistent approach: disinfectant selection should be grounded in pathogen relevance and EPA-registered claims, not a universal TB benchmark.

In 2024, the CDC refreshed its Core Infection Prevention and Control (IPC) Practices for Safe Healthcare Delivery in All Settings, directing facilities to “select EPA-registered disinfectants that have microbiocidal activity against the pathogens most likely to contaminate the patient-care environment.” That same year, TJC completed a full rewrite of the IPC chapter for hospitals, aligning requirements with CDC’s Core IPC Practices and emphasizing program governance, use of evidence-based guidelines, and demonstrated competency rather than prescriptive product requirements.

Neither CDC’s Core IPC Practices nor TJC’s revised IPC framework imposes a TB claim requirement for environmental surface disinfectants. Importantly, the historical use of a TB claim was not primarily about preventing TB transmission through surfaces. Rather, Mycobacterium tuberculosis served as a surrogate for a relatively difficult-to-inactivate organism: if a disinfectant could demonstrate activity against TB, it was historically understood to signal broad antimicrobial efficacy. Current expectations have moved away from using TB as a universal benchmark and instead emphasize selecting EPA-registered disinfectants with claims relevant to the pathogens and use conditions present in the care environment.

What our 25-state survey reveals

In 2023, Clorox Healthcare’s Clinical and Scientific Affairs team surveyed 50 healthcare-associated infection (HAI) state health coordinators to determine whether state-level regulations required healthcare disinfectants to carry a TB claim. Responses were received from 18 states, and public information was reviewed for an additional 7 states.

Across all 25 states examined, no evidence was found that hospital-grade disinfectants are required to carry a TB claim. Respondents consistently reflected three guiding principles:

• Disinfectants used should be appropriate for the type of pathogen or microorganism.
• Each hospital or healthcare organization must determine which disinfectant is appropriate.
• Facilities should follow OSHA, CDC and EPA guidance for cleaning and disinfecting.

These findings suggest that any remaining TB claim expectations within healthcare facilities are primarily internal policy artifacts, not external regulatory mandates.

Key takeaway: Across 25 states surveyed, no evidence exists that hospital-grade disinfectants are required to carry a TB claim. Remaining expectations are driven by internal facility policy — not law or regulation.

Why this matters for disinfectant selection and IPC practice

The practical stakes here are significant. When a TB claim functions as an unintentional gatekeeper, it can exclude effective and innovative surface disinfectants that address the actual pathogen risks present in modern healthcare environments, offer shorter contact times, or provide improved material compatibility with sensitive medical equipment.

Healthcare facilities should use a risk-based and indicated-use approach to disinfectant selection anchored in the following considerations:

• Organism threat relevant to the care environment (e.g., Clostridioides difficile, Candida auris)
• EPA-registered kill claims for pathogens of concern
• Product label directions and manufacturer-specified contact times
• Medical equipment instructions for use (IFU) and material compatibility
• Operational fit and workflow integration

The question healthcare facilities should be asking has changed. It is no longer “Does this disinfectant have a TB claim?” but rather “Does this disinfectant address our current pathogen risks, fit our workflows and IFU requirements and support compliant use?”

Frequently asked questions

Is a TB claim required for hospital disinfectants? Based on current federal requirements and guidance, and the 25-state review described above, a TB claim should not be treated as a universal requirement for hospital-grade environmental surface disinfectants. What does a tuberculocidal (TB) claim mean? A tuberculocidal claim means a disinfectant has demonstrated activity against Mycobacterium tuberculosis (using Mycobacterium bovis as a surrogate) under the conditions specified on the EPA-registered product label.

How should healthcare facilities choose a disinfectant? Facilities should select EPA-registered disinfectants based on the organisms most relevant to their care environment, the product’s registered claims, label directions, contact time, material compatibility, IFU requirements and workflow fit.

Why does this misconception persist? The TB claim became embedded in healthcare practice through historical disinfection frameworks, older bloodborne pathogen guidance and internal facility policies that may not have been updated as guidance evolved.

For a practical, shareable overview of this commentary, download the full study summary: Tuberculocidal Claims No Longer Reflect Disinfectant Efficacy.